

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

A MEMORIAL

REQUESTING THE DEPARTMENT OF HEALTH TO STUDY THE DISPARITIES
IN AMOUNTS OF COPAYMENTS BETWEEN ORALLY AND INTRAVENOUSLY
ADMINISTERED CHEMOTHERAPY MEDICATIONS.

WHEREAS, the emergence of clinically proven safe and
effective orally and intravenously administered anticancer
medications has significantly increased treatment options for
patients; and

WHEREAS, oncologists have significantly improved the
care of patients by utilizing both orally and intravenously
administered chemotherapy medications; and

WHEREAS, greater patient out-of-pocket cost creates a
barrier for oral anticancer therapies covered under the
pharmacy benefit of a health care plan; and

WHEREAS, intravenously administered anticancer
medications are typically covered under a health care plan's
medical benefits and require only an office visit copayment,
but orally administered chemotherapy medications are
typically covered by the prescription drug benefit and
require significant copayment or coinsurance to fill the
prescription at a pharmacy;

NOW, THEREFORE, BE IT RESOLVED BY THE SENATE OF THE
STATE OF NEW MEXICO that the department of health be
requested to identify the disparity in patient copayments

